A Phase III, Comparative, Double Blind, Randomized, Multi-centric study to compare the Efficacy, Safety and Immunogenicity of Sun's Ranibizumab with Reference Biologic in Patients with Neovascular Age-related Macular degeneration (wet AMD)
Latest Information Update: 27 Nov 2020
At a glance
- Drugs Ranibizumab (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- Sponsors Sun Pharmaceutical Industries
- 27 Nov 2020 New trial record